EXHIBIT 16.1
November 28, 2022
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC
20549, USA
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K dated November 25, 2022 of Lexaria Bioscience Corp. (the “Company”) and are in agreement with the statements contained in paragraphs 2 and 3 on Page 2 therein. We have no basis to agree or disagree with the other statements of the registrant contained therein.
Yours very truly,
DAVIDSON & COMPANY LLP
Chartered Professional Accountants
